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Summary Several studies have suggested that prolonged use of oral contraceptives may increase a woman's
risk of developing malignant melanoma. In the Royal College of General Practitioners' Oral Contraception
Study, 31 cases of malignant melanoma (code 172 - International Classification of Diseases, 8th Revision)
have been reported among ever-users and 27 cases among never-users. The risk ratio (RR) (indirectly
standardised for age, parity, social class and smoking) was 0.92 (95% confidence interval (CI) 0.55-1.54).
There was no significant trend with duration of oral contraceptive use, although those women who had used
the pill for at least 10 years had an elevated RR of 1.77 (95% CI 0.80-3.90). The Oxford/Family Planning
Association Study has recorded 15 cases among ever-users and 17 cases among never-users; the standardised
risk ratio was 0.85 (95% CI 0.42-1.70). None of the rates observed in any duration of use category was
materially different from those obsreved in never-users. The results available so far from the two studies
suggest that oral contraceptive use is probably not associated with an increased risk of malignant melanoma.
Although only one study has found an increased risk of
malignant melanoma among women who have ever used oral
contraceptives (Ramcharan et al., 1981), the results from
several others have suggested that there may be an enhanced
risk after prolonged use (Beral et al., 1977; Adam et al.,
1981; Holly et al., 1983; Beral et al., 1984). We report here
the latest findings from the Royal College of General Practi-
tioners' (RCGP) Oral Contraception Study and the Oxford/
Family Planning Association (Oxford/FPA) Contraceptive
Study.
Method
RCGP Oral Contraception Study
Full details of this study have been published elsewhere
(Royal College of General Practitioners, 1974). Briefly, dur-
ing a 14 month period starting in May 1968, 1,400 general
practitioners throughout the United Kingdom recruited
23,000 women who were using the contraceptive Pill and a
similar number who had never used it. The two groups were
matched for age, and all subjects were married or living as
married. At 6-monthly intervals since recruitment, the
general practitioner has supplied for each woman still under
observation details of any oral contraceptives prescribed and
all newly presenting episodes of illness.
Oxford/Family Planning Association Contraceptive Study
During the period 1968 to 1974, 17,032 white married women
aged 25 to 39 were recruited at 17 family planning clinics in
different parts of England and Scotland. On entry, 9,653
(56%) were taking oral contraceptives, 4,217 (25%) were
using a diaphragm, and 3,162 (19%) were using an intra-
uterine device. These women are being followed up at the
clinics and by post, telephone, or home visiting. Information
collected about each woman during follow-up is coordinated
at each clinic by a research assistant, and includes details of
pregnancies and their outcome, changes in contraceptive
practices, and reasons for referral to hospital as an out-
patient or inpatient. Diagnoses on discharge from hospital
are confirmed by obtaining copies of discharge summaries or
letters. Certain subgroups of women have not been followed
up in detail beyond the age of 45 years, but this practice has
not influenced the results now reported. Full details of the
Study have been described elsewhere (Vessey et al., 1976).
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During the course of each Study, three oral contraceptive
user groups have evolved; current user, former user and
never-user. Each woman's contraceptive status can change,
and, therefore, she might have contributed periods of observ-
ation to each of the three groups. For each calendar month
in which a subject uses the pill, I month is added to the
period of exposure of current users. If that woman stops the
pill, her subsequent periods of observation are included in
the former user group unless she restarts use, in which case
she again contributes from the date of change to the current
users' period of observation. If a woman who had never used
oral contraceptives at recruitment subsequently starts to use
the pill, her experience is, thereafter, allocated to the appro-
priate user group. In the present analyses, the current and
former users were combined to form an ever-user group.
The results relate to all cases ofmalignant melanoma (code
172, International Classification of Diseases, 8th Revision)
which occurred for the first time during each study; cases
diagnosed before recruitment or (in the RCGP Study) during
pregnancy were excluded (together with the associated
periods of observation). Each case was categorised according
to the woman's contraceptive status at the time of the event.
Unless stated otherwise, the incidence rates were indirectly
standardised for age and partity at diagnosis, and social class
and smoking at recruitment, using the total population in
each study as the reference population. Confidence intervals
were calculated on the assumption that the standard devia-
tion of the log relative risk is equal to the sum of the
reciprocals of the observed number of cases in the two
groups being compared. Tests for linear trends are based on
Mantel's (1963) method, modified to accommodate standard-
ised data. The RCGP results use data available at May 1990,
while the Oxford/FPA findings relate to data at December
1989.
Results
In both studies, the rate of melanoma in ever-users was not
materially different from that in never-users (Table I). Within
the RCGP data there was a suggestion of an increaseed risk
among those women who had used oral contraceptives for 10
years or more. The confidence interval around the risk ratio,
however, was wide and included unity, indicating that chance
may be the explanation for the finding. Furthermore, there
was no significant trend of increasing risk with duration of
use. Seven cases of melanoma were diagnosed while the
woman was still using oral contraceptives, and 24 occurred
after the woman had stopped. In the Oxford/FPA data none
of the rates observed in any duration of use category were
materially different from that seen in never-users. Unex-
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Table I Standardised rates of melanoma (ICD Code 172) by duration of ever-use of oral
contraceptives
Duration of ever-use (months)
Never-users 1-59 60-119 120 + All ever-use
RCGP data
Standardised rate* (No.) 0.13 (27) 0.10 (15) 0.09 (8) 0.23 (8)t 0.12 (31)
Risk relative to never-users 0.77 0.69 1.77 0.92
95% Confidence Interval (0.41 -1.45) (0.31 -1.52) (0.80-3.90) (0.55- 1.54)
Woman-years of observation 197,201 176,160 81,224 27,498 284,882
Oxford/FPA data
Standardised rate* (No.) 0.13 (15) 0.08 (5) 0.14 (8) 0.13 (4)$ 0.11 (17)
Risk relative to never-users 0.56 1.02 0.98 0.82
95% Confidence Interval (0.16- 1.63) (0.37-2.56) (0.24-3.09) (0.38- 1.76)
Woman-years of observation 101,520 70,076 66,269 29,000 165,346
'Indirectly standardised for age and parity at diagnosis, social class and smoking habits at
recruitment; expressed as rates per thousand woman-years. tTest for trend, x2 = 0.17, P >0.05. $Test for
trend, x2=0.01, P>0.05.
pectedly, among women who had used the oral contracep-
tives, all the cases of melanoma occurred in former pill users.
Table II presents the incidence rates for melanoma from
both studies by time since last use. Neither study was able to
demonstrate a relationship between time since stopping oral
contraceptives and the risk of malignant melanoma.
There was no difference between the site distribution of
melanomas found in ever-users and that found in never-
users. The lower limb was the site most frequently specified
(43% in the RCGP Study, 60% in the Oxford/FPA Study).
We are unable to determine whether or not oral contracep-
tives influence the development of any particular histological
type of malignant melanoma, since adequate details were not
available to either study.
The data from both studies were analysed according to the
oestrogen and progestogen content of the oral contraceptives
used. There was no evidence of an increased risk with any
particular formulation.
Ten of the patients in the RCGP Study died from mela-
noma (six ever-users, four never-users). The 5-year survival
rate was 86%. In the Oxford/FPA Study, there were only
two deaths, one in each of the comparison groups.
Gallagher et al. (1985) have previously found a significant
inverse association between number of live births and risk of
melanoma. A similar trend was perhaps suggested by both
sets of data, although on formal testing the results did not
approach statistical significance (Table III). The RCGP
results revealed a significant inverse relationship between
melanoma risk and social class (Table IV). This was not
apparent in the Oxford/FPA data, although the incidence
was lowest in social classes IV and V. Smoking did not
influence melanoma risk in either study (data not shown).
Discussion
These results from two large prospective cohort studies pro-
vide little indication that use of oral contraceptives, even for
prolonged durations, is associated with an increased risk of
malignant melanoma. This is in agreement with the evidence
from most other groups (Gallagher et al., 1985; Bain et al.,
1982; Holman et al., 1984; Helmrich et al., 1984).
Ramcharan and her colleagues (1981) updated the pre-
liminary findings (Beral et al., 1977) from the Walnut Creek
Contraceptive Drug Study conducted in California. The risk
of melanoma among ever-users was three times that of never-
users. Although this elevation was statistically significant,
there was no relationship between the risk and duration of
pill use. Furthermore, the increase may have been due to
confounding: supplementary questionnaires issued during the
study found that users of the pill sunbathed more frequently
and were more likely to expose themselves to the sun than
never-users and sun exposure is an important risk factor for
the development of malignant melanoma. Unfortunately,
since these data were not collected from all subjects recruited
to the study, the authors were unable to adjust their results
for these important differences.
Two other studies have found significantly elevated risks
among certain subgroups of women. Holly and co-workers
(1983) found a highly significant relationship between the risk
of developing superficial spreading melanoma and duration
of pill use. Among those women who had used oral contra-
ceptives for at least 5 years, there was also a trend of
increasing risk the longer the interval since first or last use.
Unfortunately, once again the authors were unable to adjust
their results for the potential confounding effect of sun
exposure. Another more recent study, which was able to
make these adjustments, did not show any association
between pill use and superficial spreading melanoma (Helm-
rich et al., 1984).
In an Australian case-control study (Beral et al., 1984),
oral contraceptives did not generally increase the risk of
melanoma, but those women who had used them for more
than 5 years, starting at least 10 years before the diagnosis,
had a 50% elevation in risk. This increase remained statis-
tically significant even after adjustment for many factors,
including eye, hair and skin colour, level of outdoor activity
and history of sunburning. The authors suggest that pro-
Table II Standardised rates of melanoma (ICD Code 172) by time since last use of oral
contraceptives
Months since last use
1-23 24-47 48-71 72 +
RCGP data
Standardised rate* (No.) 0.16 (4) 0.11 (3) 0.23 (6) 0.11 (11) t
Woman-years of observation 32,280 30,025 26,963 89,564
Oxford/FPA data
Standardised rate' (No.) 0.07 (2) 0.17 (3) 0.31 (5) 0.17 (7) +
Woman-years of observation 29,642 21,125 18,163 40,614
Indirectly standardised for age and parity at diagnosis, social class and smoking habits
at recruitment; expressed as rates per thousand woman-years. tTest for trend, x2 = 0.31,
P >0.05. +Test for trend, X2= 1.15, P >0.05.432 P.C. HANNAFORD et al.
Table III Standardised rates of melanoma (ICD Code 172) by parity
Parity
0 1 2or3 4+
RCGP data
Standardised rate* (No.) 0.17 (5) 0.14 (9) 0.12 (37) 0.09 (7)t
Woman-years of observation 34,797 70,415 301,896 74,974
Oxford/FPA data
Standardised rate* (No.) 0.16 (4) 0.10 (4) 0.12 (22) 0.09 (2)t
Woman-years of observation 25,109 38,207 180,297 23,252
Indirectly standardised for age and pill status at diagnosis, social class and smoking
habits at recruitment; expressed as rates per thousand woman-years. tTest for trend,
X2 = 1.38, P >0.05. :Test for trend, X2 = 0.23, P >0.05.
Table IV Standardised rates of melanoma (ICD Code 172) by social class
Social class
III
I or II (Manual & non-manual) IV or V
RCGP data
Standardised rate' (No.) 0.21 (26) 0.09 (24) 0.09 (8)t
Woman-years of observation 107,772 272,570 95,614
Oxford/FPA data
Standardised rate' (No.) 0.11 (13) 0.14 (18) 0.05 (1)$
Woman-years of observation 108,635 131,363 26,867
Indirectly standardised for age, pill status and parity at diagnosis, and smoking habits
at recruitment; expressed as rates per thousand woman-years. tTest for trend, x2 = 7.46,
P<0.01. ITest for trend, X2=0.004, P>0.05.
longed oral contraceptive use may, after a lag of 10 years or
so, increase the risk ofmalignant melanoma. We were unable
directly to test this hypothesis because of the relatively small
number of cases currently reported to each study. There was,
however, no evidence in either study for a trend ofincreasing
risk of malignant melanoma with time since last use (Table
II).
It is important to consider the potential biases which might
have affected our results. The RCGP Study has suffered from
a greater loss of follow-up than the Oxford/FPA Study;
31,000 women are no longer under observation, mostly
because they have moved from the recruiting doctor's prac-
tice area. Those no longer under observation tend to be
younger, of lower parity and higher social class than those
remaining in the study. The characteristics of ever-users who
have been lost to follow-up, however, are very similar to
those of never-users who have also been lost, and so valid
comparison can still be made between the two contraceptive
groups. It seems unlikely, therefore, that loss to follow-up
has biased the results. Both studies have collected data pros-
pectively, so recall bias would not affect the findings.
Although the rates of melanoma reported in both studies are
higher than expected from national figures (Office of Popula-
tion Censuses and Surveys, 1984), this may reflect the
incomplete recording of melanomas in cancer registries. A
separate study has shown that approximately 40% of
melanomas reported to the Oxford/FPA Study were not
registered (Villard-Mackintosh et al., 1988).
The 5-year survival rate reported from the RCGP Study
was better than that published in the Office of Population
Censuses and Survey's Longitudinal Survey (1990), while
only two women with melanoma in the Oxford/FPA Study
have died. This may reflect the fact that both studies had an
over-representation of women from the higher social classes
(Royal College of General Practitioners, 1974; Vessey et al.,
1976), and survival from melanoma has been shown to be
related to socioeconomic status (Office of Population Cen-
suses and Surveys, 1990).
The opportunity has been taken to investigate whether or
not the risk ofdeveloping melanoma was related to a number
of other factors. There was some suggestion that increasing
parity may reduce the risk of melanoma. This supports the
findings of other workers (Holly et al., 1983; Gallagher et al.,
1985; Holman et al., 1984). Gallagher et al. (1985) found a
significant inverse trend of melanoma risk with parity, which
was unrelated to age at first full-term birth. The protective
effect of pregnancy, however, was not apparent until a
woman had had three or more children. A similar but non-
significant protective effect of pregnancy among women who
have had at least five children has also been reported in other
studies (Holly et al., 1983; Holman et al., 1984). It is difficult
to know how pregnancy might exert its protective effect.
Perhaps women who have many children have less exposure
to the sun.
Results from the RCGP study also revealed a clear trend
of elevated risk among women in the higher social classes.
Although this has been found elsewhere (Lee & Strickland,
1980), there has been a relative paucity of data concerning
the relationship between melanoma risk in women and social
class. It is intriguing to speculate why there should be such a
trend; perhaps it reflects important differences in the level of
sun exposure experienced by women in different socio-
economic groups.
It must be remembered that malignant melanoma is rare.
Thus, although both the RCGP and Oxford/FPA studies
have observed a large number of women who have used the
pill for substantial lengths of time, they could still miss a
small increase in risk among pill users. The evidence from
these and other studies, however, suggests that the use of oral
contraceptives is not an important risk factor for malignant
melanoma.
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